commercial spaceflight
Auto Added by WPeMatico
Space manufacturing startup Varda inks deal with Rocket Lab for three spacecraft
Orbital manufacturing startup Varda Space Industries is moving fast. Only a few weeks after announcing a $42 million Series A, Varda has signed a deal with launch company Rocket Lab for three Photon spacecraft to support the startup’s initial missions.
The first spacecraft will be delivered in the first quarter of 2023, with the second to follow later that year and the third in 2024. It’s an aggressive schedule for the eight-month-old Varda and would mark the company’s first three manufacturing missions to space. The contract includes an option for Varda to purchase a fourth Photon.
Partnering with a more established company makes sense — especially considering the Photon’s bona fides, which includes a NASA-funded mission to the moon at the end of the year. Rocket Lab was also awarded a subcontract by the University of California Berkeley Space Sciences Laboratory to design two Photon spacecraft for a one-year mission to Mars.
Image Credits: Rocket Lab (opens in a new window)
Varda, which was founded by SpaceX veteran Will Bruey and Founders Fund principal Delian Asparouhov, is banking big on a manufacturing condition that you can only find in space: microgravity. They think that the potential market for bioprinted organs, specialized semiconductors, fiber-optic cables or pharmaceuticals — products that you can’t make in Earthbound-conditions — is high enough to make the costs of building a spacecraft and launching to space more than worth it.
Under this most recent deal, each Photon will be outfitted with two Varda-made modules: The first will be a microgravity manufacturing module, where the space production will actually take place, and the second will be a reentry capsule designed to bring those finished products back to Earth. Asparouhov told TechCrunch that the are designing the reentry modules to bring back “on the order of 40-60 kilograms of materials” for the first couple of missions, with the aim of quickly scaling up for subsequent launches.
Varda says this approach is low-risk and incremental. “That’s why we’re seeing so much interest from the investment community, [the Department of Defense], NASA, et cetera, it’s this very pragmatic, one-step-at-a-time approach,” Asparouhov said. “We’ll prove this first space factory. And yes, as we start to scale it allows us to send a larger space factory and then eventually, yes, we might have something the size of the [International Space Station], 10 times the size of the ISS. But that’s not what we’re starting with. We’re starting with a very small, near-term pragmatic approach.”
Each mission will last roughly three months from launch to landing, Rocket Lab said in a statement.
Powered by WPeMatico
Japanese startup ispace raises $46M to support planned moon missions
Japanese startup ispace has raised $46 million in a fresh round of Series C funding as it looks to complete three lunar lander missions in three years.
The funding will go toward the second and third of the planned missions, scheduled for 2023 and 2024. The first mission, which ispace aims to conduct in the latter half of 2022, is being furnished by earlier financing.
The Series C was led by Japanese VC firm Incubate Fund, with additional investment from partnerships managed by Innovation Engine, funds managed by SBI Investment Co., Katsunori Sago, Aizawa Investments and funds managed by HiJoJo Partners and Aizawa Asset Management. Incubate Fund’s investments in ispace stretch back to the company’s seed round in 2014.
Ispace’s total funding now stands at $195.5 million.
The company said last month it had started building the lunar landing flight module for the 2022 mission at a facility owned by space launch company ArianeGroup, in Lampoldshausen, Germany. The lander for that first mission, the Hakuto-R, will take three months to reach the moon, largely to save costs and additional weight from propellant. It will deliver a 22-pound rover for Saudi Arabia’s Mohammed bin Rashid Space Center, a lunar robot for the Japan Aerospace Exploration Agency and payload from three Canadian companies. The lander will reach the moon aboard a SpaceX Falcon 9 rocket.
The 7.5 foot-tall Hakuto-R will also be used in the second mission in 2023, to deposit a small ispace rover that will collect data to support the company’s subsequent missions to the moon. For the final mission, the Toyko-based startup is developing a larger lander in the United States.
Ispace describes its long-term goal as being a “gateway for private sector companies to bring their business to the Moon.” The company has particular interest in helping spur a space-based economy, noting on its website that the moon’s water resources represent “untapped potential.”
Powered by WPeMatico
Accion Systems raises $42 million in Series C to accelerate development of 4th-gen propulsion system
Space propulsion developer Accion Systems has closed its most significant funding round yet. The company raised $42 million in a Series C led by Tracker Capital, bringing its valuation to $83.5 million.
Along with the investment, Tracker Capital also acquired a majority stake in the company. This latest injection of capital will facilitate the development and manufacturing of the company’s fourth generation propulsion system, dubbed the tiled ionic liquid electrospray (TILE) system.
The TILE system uses electrical energy to push charge particles (ions) out its back to generate propulsion. While ion engines have been around for decades, Accion uses a liquid propellant, an ionic liquid salt, instead of gas. The liquid is inert and nonpressurized, meaning there’s no risk of explosion. It also results in a product that doesn’t need bulky components like ionization chambers, and an overall smaller and lighter weight system relative to the spacecraft — key considerations in space, where every gram of payload has a high price tag.
“It lets us build really, really small systems,” Accion co-founder Natalya Bailey explained to TechCrunch. “Instead of trying to take an existing ion engine the size of a Prius and shrink it down, we can start with very small systems because of this propellant.” And she does mean small — each thruster tile is about the size of a postage stamp.
The TILE system is also scalable and modular, meaning it could feasibly be used on anything from CubeSats to propelling an interplanetary spacecraft, Accion CEO Peter Kant added in a recent interview with TechCrunch. “It’s one of the few occasions where the total addressable market and the actual addressable market that we can serve are pretty closely aligned and almost overlap,” he said.
The newest generation of the TILE system is the same size as its predecessors, but Accion is increasing the number of emitters on a given chip — emitters being the technology that actually shoots out the ions, generating the momentum — by almost tenfold. “We get more ions per area and that gives us a whole lot more thrust with the same amount of space,” Kant said.
Accion is looking to ship the first fourth-gen thruster systems in the middle to late summer of 2022.
The TILE system was developed by Accion co-founders Natalya Bailey and Louis Perna while the two were at the Massachusetts Institute of Technology. The tech generated a ton of interest from big aerospace companies, but they decided to found Accion in 2014 rather than sell. The company manufactures and assembles its product at its facility in Charlestown, Massachusetts.
The TILE system was onboard commercial spacecraft, one with Astra Digital and one with NanoAvionics, that went up on SpaceX’s Transporter-2 launch at the end of June. Accion started by focusing on serving smaller spacecraft first, like CubeSats, but Bailey said that was just the beginning.
“We’re going after that segment initially, and then intending to reinvest our learnings in building larger and larger systems that eventually can do big geostationary satellites and interplanetary missions and so on. The systems that went up on the most recent launcher [is] probably good for a satellite up to about 50 kilograms [ … ] For us, it’s on the smaller end of where we intend to go.”
Powered by WPeMatico
SpaceX cautions on launch regulation that outpaces innovation
During the Federal Aviation Administration’s (FAA) 23rd annual Commercial Space Transportation Conference in Washington, D.C., one panel focused on the changing regulatory environment when it comes to private launch activities, and how those are integrated into existing rules and practices for managing commercial air transportation. Panelist Caryn Schenewerk, SpaceX senior counsel and senior director of space flight policy, emphasized that while the company always does the utmost to ensure safety in everything it does, the company also wants to focus on the actual state of the industry today and how it needs to grow as various partners work to establish new rules for the growing commercial launch sector.
“When aviation started, the Wright brothers weren’t flying over major populated cities,” Schenewerk pointed out. “They were outside Paris in an unpopulated field, and they were at Kitty Hawk on unpopulated beaches. And they were in Ohio in unpopulated areas.”
Schenewerk was directly addressing comments made by other panelists, and specifically ALPA Aviation Safety Chair Steve Jangelis, that suggested the emerging commercial launch industries may be looking far ahead to when they’re launching from spaceports located near populated areas, and launching with much more frequency than they are today. In general, Jangelis was advocating for laying the groundwork now for high levels of cooperation and integration between aviation traffic management and rocket launch operators.
Schenewerk was reluctant to concede any kind of direct equivalency between the commercial air transportation industry and the space launch sector, given their relative dissimilarity.
She noted that in terms of sheer volume, there’s a massive difference, with roughly 40 to 50 launches set for 2020 compared to millions of flights for commercial air. Airlines also use essentially the same small handful of airframes from suppliers like Boeing and Airbus, while each launch company has their own, very different vehicle with different conditions for launch and flight. Overall, she suggested then that anticipating some potential future state where the industries were more similar could result in stifling progress toward that ultimate goal.
“I hope we get to that million launches at some point, but when we are at that point, it’s going to be because we worked our way up the safety trajectory in a way that allows us to operate that way,” Schenewerk said. “Today, SpaceX can’t fly from a spaceport in the middle of the country, because we won’t get through the safety approval. We literally will not be licensed by the FAA to operate from that site, because we will then be flying over large populations of people — and we aren’t at that level of reliability and safety in this industry to fly over large populations of people with these kinds of rockets. Could we get there someday? Yeah, we can get there someday when we’ve had a million flights, and a million prove-outs of our capability, when we have such repeatability that we’re in that level.”
Ultimately, Schenewerk’s comments and Jangelis’ responses illustrate that there are still a lot of places where younger companies and emerging technologies like reusable rocket launches are conflicting with the views of more established industries and players operating in some shared spaces.
FAA Administrator Steve Dickson also addressed the agency’s ongoing work to establish launch rules, which were released as a draft last year and which Dickson said will likely be finalized sometime this fall, once the FAA has incorporated industry comments and feedback.
“Let’s think about that big vision, that big day when lots of things are happening,” Schenewerk said. “But let’s also not yell at our kid for not being able to fly an airplane when they can barely walk — and I think that’s where we are right now: We’re still figuring out how to walk and run in this industry.”
Powered by WPeMatico
Luna is a new kind of space company helping biotech find its footing in microgravity
Toronto-based startup Luna Design and Innovation is a prime example of the kind of space company that is increasingly starting up to take advantage of the changing economics of the larger industry. Founded by Andrea Yip, who is also Luna’s CEO, the bootstrapped venture is looking to blaze a trail for biotechnology companies who stand to gain a lot from the new opportunities in commercial space – even if they don’t know it yet.
“I’ve spent my entire career in the public and private health industry, doing a lot of product and service design and innovation,” Yip told me in an interview. “I was working in pharma[ceuticals] for several years, but at the end of 2017, I decided to leave the pharma world and I really wanted to find a way to work along the intersection of pharma, space and design, because I just believe that the future of health for humanity is in space.”
Yip founded Luna at the beginning of this year to help turn that belief into action, with a focus on highlighting the opportunities available to the biotechnology sector in making use of the research environment unique to space.
“We see space as a research platform, and we believe that it’s a research platform that can be leveraged in order to solve healthcare problems here on Earth,” Yip explained. “So for me, it was critically important to open up space to the biotech sector, and to the pharma sector, in order to use it as a research platform for R&D and novel discovery.”
The International Space Station has hosted a number of pharma and biotech experiments.
NASA’s work in space has led to a number of medical advances, inducing digital imaging tech used in breast biopsy, transmitters used for monitoring fetus development within the womb, LED’s used in brain cancer surgery and more. Work done on researching and developing pharmaceuticals in space is also something that companies including Merck, Proctor & Gamble and other industry heavyweights have been dabbling in for years, with experiments conducted on the International Space Station. Companies like SpaceFarma have now sent entire minilaboratories to the ISS to conduct research on behalf of clients. But it’s still a business with plenty of remaining under-utilized opportunity, according to Yip – and tons of potential.
“I think it’s a highly underutilized research platform, unfortunately, right now,” she said. “When it comes to certain physical and life sciences phenomena, we know that things behave differently in space, in what we refer to as microgravity-based environments […] We know that cancer cells, for instance, behave differently in short- and longer-term microgravity when it comes to the way that they metastasize. So being able to even acknowledge that type of insight, and try and understand ‘why’ can unlock a lot of new discovery and understanding about the way cancer actually functions […] and that can actually help us better design drugs, and treatment opportunities here on Earth, just based on those insights.”
Blue Origin’s New Shepard rocket. Credit: Blue Origin .
Yip says that while there has been some activity already in biotech and microgravity, “we’re on the early end of this innovation,” and goes on to suggest that over the course of the next ten or so years, the companies that will be disrupting the existing class of legacy big pharma players will be ones who’ve invested early and deeply in space-based research and development.
The role of Luna is to help biotech companies figure out how best to approach building out an investment in space-based research. To that end, one of its early accomplishments is securing a role as a ‘Channel Partner’ for Jeff Bezos’ commercial space launch company Blue Origin. This arrangement means that Luna acts a a sales partner for Blue Origin’s New Shepard suborbital rocket, working with potential clients for the Amazon founder’s rocket company on how and why they might seek to set up a sub-orbital space-based experiment.
That’s the near-term vision, and the way that Luna will seek to have the most impact here on Earth. But the possibilities of what the future holds for the biotech sector start to really open up once you consider the current trajectory of the space industry, including NASA’s next steps, and efforts by private companies like SpaceX to expand human presence to other planet.
“We’re talking about going back to the Moon by 2024,” Yip says, referring to NASA’s goal with its Artemis program. “We’re talking about going to Mars in the next few years. There’s a lot that we will need to uncover and discover for ourselves, and I think that’s a huge opportunity. Who knows what we’ll discover when we’re on other planets, and we’re actually putting people there? We have to start preparing for that and building capability for that.”
Powered by WPeMatico